Volume 19, Number 1—January 2013
CME ACTIVITY
Pneumocystis jirovecii Genotype Associated with Increased Death Rate of HIV-infected Patients with Pneumonia
Table 1
Pneumocystis jiroveci dihydropteroate synthase genotype distribution according to clinical parameters of 112 cases of pneumonia in 110 HIV-positive patients from 5 university hospitals in Lyon, France*
| Wild type, n = 75 | M2, n = 17 | M3, n = 20 | ||
|---|---|---|---|---|
| Age at PCP diagnosis, y | ||||
|
1–40 |
41 | 10 | 14 | 0.62 |
|
41–60 |
31 | 7 | 5 | |
|
61–80 |
3
|
0
|
1
|
|
| Sex | ||||
|
M |
62 | 14 | 19 | 0.38 |
|
F |
13
|
3
|
1
|
|
| Diagnosis year | ||||
|
1993 |
6 | 2 | 0 | 0.58 |
|
1994 |
24 | 3 | 4 | |
|
1995 |
20 | 5 | 6 | |
|
1996 |
25
|
7
|
10
|
|
| CD4 cell count, median cells/μL† | ||||
|
0–50 |
42 | 15 | 11 | 0.05 |
|
51–100 |
17 | 0 | 4 | |
|
>100 |
10
|
0
|
2
|
|
| First-line treatment | ||||
|
SMX/TMP |
59 | 14 | 15 | 0.90 |
|
Pentamidine or atovaquone |
14 | 3 | 5 | |
|
Others |
2
|
0
|
0
|
|
| SMX/TMP allergy | ||||
|
Yes |
4 | 0 | 3 | 0.27 |
|
No |
71
|
17
|
17
|
|
| Corticotherapy at PCP diagnosis | ||||
|
Yes |
18 | 1 | 3 | 0.25 |
|
No |
57
|
16
|
17
|
|
| Mechanical ventilation at PCP diagnosis | ||||
|
Yes |
11 | 0 | 3 | 0.26 |
|
No |
64
|
17
|
17
|
|
| P. jirovecii SSCP type 1 | 3 | 6 | 1 | <0.001 |
|
7 |
3 | 0 | 6 | |
|
10 |
2 | 1 | 1 | |
|
Others |
30 | 3 | 3 | |
|
Co-infected |
37
|
7
|
9
|
|
| Outcome within 1 month | ||||
|
Favorable |
61 | 16 | 14 | 0.39 |
|
Death attributed to PCP |
12 | 1 | 5 | |
|
Death not attributed to PCP |
2 | 0 | 1 |
*Data derived from Fisher’s exact test. DHPS, dihydropteroate synthase; M, mutation; SSCP, single-strand conformation polymorphism; PCP, P. jirovecii pneumonia; SMX/TMP, sulfamethoxazole and trimethoprim.
†Data missing for 11 patients.
